The natural history of impaired glucose tolerance in the Pima Indians - PubMed (original) (raw)
The natural history of impaired glucose tolerance in the Pima Indians
M F Saad et al. N Engl J Med. 1988.
Abstract
Among 384 Pima Indians with impaired glucose tolerance according to World Health Organization criteria who were followed for 1.6 to 11.5 years (median, 3.3), non-insulin-dependent diabetes mellitus (NIDDM) developed in 118 (31 percent), glucose tolerance remained impaired in 100 (26 percent), and glucose tolerance returned to normal in 166 (43 percent). The cumulative incidence of NIDDM was 25 and 61 percent at 5 and 10 years, respectively. The risk of development of diabetes was 6.3 times (95 percent confidence interval, 3.8 to 10.6) as high as in a normoglycemic control group (n = 752). Variables predicting deterioration to NIDDM were age up to the age of 40, after which increasing age had a beneficial effect; higher plasma glucose levels during fasting and after carbohydrate loading; and higher serum insulin levels after fasting and lower levels after carbohydrate loading, suggesting that insulin resistance and decreased beta-cell responsiveness are important determinants of the clinical outcome of impaired glucose tolerance. Obese subjects had 2.9 times (95 percent confidence interval, 2.0 to 10.9) the incidence of NIDDM as the nonobese. Obesity was not, however, predictive of progression to NIDDM after an adjustment for plasma glucose and serum insulin levels. We conclude that in this population approximately one fourth of subjects with impaired glucose tolerance have NIDDM at five years and two thirds at 10 years (approximately one third revert to normal) and that age and plasma glucose and insulin levels are the best predictors of clinical outcome.
Similar articles
- Insulin and hypertension. Relationship to obesity and glucose intolerance in Pima Indians.
Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Saad MF, et al. Diabetes. 1990 Nov;39(11):1430-5. Diabetes. 1990. PMID: 2227116 - The effect of parity on the later development of non-insulin-dependent diabetes mellitus or impaired glucose tolerance.
Kritz-Silverstein D, Barrett-Connor E, Wingard DL. Kritz-Silverstein D, et al. N Engl J Med. 1989 Nov 2;321(18):1214-9. doi: 10.1056/NEJM198911023211802. N Engl J Med. 1989. PMID: 2797087 - Hyperinsulinaemia is a predictor of non-insulin-dependent diabetes mellitus.
Zimmet P, Dowse G, Bennett P. Zimmet P, et al. Diabete Metab. 1991 May;17(1 Pt 2):101-8. Diabete Metab. 1991. PMID: 1936464 Review.
Cited by
- The Role of Selenium Nanoparticles in Addressing Diabetic Complications: A Comprehensive Study.
Satpathy S, Panigrahi LL, Arakha M. Satpathy S, et al. Curr Top Med Chem. 2024;24(15):1327-1342. doi: 10.2174/0115680266299494240326083936. Curr Top Med Chem. 2024. PMID: 38561614 Review. - Prevalence of prediabetes by the fasting plasma glucose and HbA1c screening criteria among the children and adolescents of Shenzhen, China.
Yang C, Li S, Wu L, Ding Z, Zhou H, Pan Y, Yang C, Lin J, Li Q, You Y, Zhong X, Chen Y, Zhao Y. Yang C, et al. Front Endocrinol (Lausanne). 2024 Jan 19;15:1301921. doi: 10.3389/fendo.2024.1301921. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38313368 Free PMC article. - Diagnostic criteria and etiopathogenesis of type 2 diabetes and its complications: Lessons from the Pima Indians.
Looker HC, Chang DC, Baier LJ, Hanson RL, Nelson RG. Looker HC, et al. Presse Med. 2023 Mar;52(1):104176. doi: 10.1016/j.lpm.2023.104176. Epub 2023 Sep 30. Presse Med. 2023. PMID: 37783422 Free PMC article. Review. - Elevated triglyceride-glucose (TyG) index predicts impaired islet β-cell function: A hospital-based cross-sectional study.
Chen Z, Wen J. Chen Z, et al. Front Endocrinol (Lausanne). 2022 Sep 30;13:973655. doi: 10.3389/fendo.2022.973655. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246870 Free PMC article. - Effects of a Diabetes Prevention Program on Type 2 Diabetes Risk Factors and Quality of Life Among Latino Youths With Prediabetes: A Randomized Clinical Trial.
Peña A, Olson ML, Hooker E, Ayers SL, Castro FG, Patrick DL, Corral L, Lish E, Knowler WC, Shaibi GQ. Peña A, et al. JAMA Netw Open. 2022 Sep 1;5(9):e2231196. doi: 10.1001/jamanetworkopen.2022.31196. JAMA Netw Open. 2022. PMID: 36094502 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical